Dr. Gurwith has previously served as Chief Medical Officer at PaxVax since 2007. During his 30 years in industry at major pharmaceutical companies (Boehringer Mannheim, Wyeth Ayerst Pharmaceuticals) and biotechnology companies (VaxGen, Genelabs, and Sequus), Dr. Gurwith has directed the clinical development of 20 therapeutic drug candidates in the areas of infectious diseases, cardiovascular, cancer, inflammation, and metabolic disorders. He played a pivotal role in the regulatory submissions in the U.S. and Europe, ultimately securing the approval of four new agents: RotaShield® (vaccine), Amphocil® (antibiotic), Demadex® (antihypertensive), and Retavase® (cardiovascular). Dr. Gurwith has authored 95 publications and served as a reviewer for several prestigious peer-reviewed journals, such as The Journal of Infectious Diseases and The Journal of the American Medical Association. Dr. Gurwith has an M.D. from Harvard University, Board certifications in internal medicine, infectious diseases and microbiology, and a J.D. from Temple University School of Law.